Evaxion Biotech A/S (EVAX) Stock Analysis & Investment Frameworks
Evaxion Biotech A/S (EVAX) stock analysis on Invetso. Review Evaxion Biotech A/S’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Evaxion Biotech A/S Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: DK
Evaxion Biotech A/S Key Financial Metrics
- Market Cap: $23.43M
- Revenue: $7.53M
- ROE: -61.39%
- ROIC: -46.68%
- Dividend Yield: N/A
About Evaxion Biotech A/S
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Evaxion Biotech A/S Investment Frameworks
Invetso analyzes Evaxion Biotech A/S (EVAX) across the following frameworks:
- Evaxion Biotech A/S 10Y Growth Potential
- Evaxion Biotech A/S Scenario Analysis
- Evaxion Biotech A/S Risks & Opportunities
- Evaxion Biotech A/S Economic Moat
- Evaxion Biotech A/S Business Model
- Evaxion Biotech A/S Management
- Evaxion Biotech A/S SWOT Analysis
- Evaxion Biotech A/S Porter's 5 Forces
- Evaxion Biotech A/S PESTLE Analysis
- Evaxion Biotech A/S ESG Analysis